Nationwide survey on activities of regional core centers for the management of liver disease in Japan: Cumulative analyses by the Hepatitis Information Center 2009–2017

Setoyama, Hiroko; Korenaga, Masaaki; Kitayama, Yuko; Oza, Noriko; Masaki, Naohiko; Kanto, Tatsuya

doi:10.1111/hepr.13458

Cited by 9 publications

(9 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Hepatitis Information Center 9,10 of the National Center for Global Health and Medicine started a retrospective cohort study to construct the Japanese DAAs Database in October 2014. All 47 prefectural governments were invited to join this project; 18 prefectures participated and sent data to the Hepatitis Information Center.…”

Section: Methodsmentioning

confidence: 99%

Characteristics of patients aged over 75 years with hepatitis C virus infection treated with direct‐acting antivirals in Japan: Evidence based on the nationwide, real‐world database in Japan

Masaki

Kawasaki

Nozaki

et al. 2021

Hepatology Research

Self Cite

View full text Add to dashboard Cite

Aim Direct‐acting antivirals (DAAs) have dramatically changed the treatment of chronic hepatitis C. Their high efficacy helps in eradicating hepatitis C virus with few adverse events. Information on real‐world use of DAAs therapy in patients aged 75 years and older is inadequate. Methods The Japanese DAAs database was constructed in 2014 as a cooperative system between 18 prefectures. The medical reports filled in by doctors and anonymized at the local government office were collected. The patients' demographic features, viral factors, and treatment characteristics were compared among three groups stratified by age when therapy was initiated: Group A (<60 years old), Group B (60–74 years old), and Group C (≥75 years old). Results Out of the 22,454 patients whose age upon starting therapy could be identified, 24.8% (n = 5597) belonged to Group C, which was ten times the number in the Japanese Interferon Database. Female patients, advanced stages of liver fibrosis, and past history of hepatocellular carcinoma treatment were significantly higher in the older age groups (Group A < B < C), whereas sustained virologic response (SVR) rates were not different (91%–93%). In Group C, multivariate logistic regression analysis revealed that predicting factors for virologic response varied among DAAs regimens. However, the completion of DAAs therapy commonly contributed to SVR, regardless of DAAs regimen. Conclusions DAAs therapy is associated with high SVR rates, even in the oldest age group, and therapy should not be withheld on the basis of old age.

show abstract

Section: Methodsmentioning

confidence: 99%

Characteristics of patients aged over 75 years with hepatitis C virus infection treated with direct‐acting antivirals in Japan: Evidence based on the nationwide, real‐world database in Japan

Masaki

Kawasaki

Nozaki

et al. 2021

Hepatology Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Consultations provided at the liver disease consultation and support centers of core hospitals cover a wide range of topics. The most common topics are medical expense subsidy systems, treatment, and the disease itself, and there has been recent growth in the number of consultations on things to keep in mind in daily life as well as medical institutions, livelihood support, and hepatitis-related lawsuits (13). In response to the need to improve the consultation system for hepatitis patients in various situations, the Consultation Support System for Patients with Liver Diseases was introduced at core hospitals across Japan in July 2018 to provide consultation support for hepatitis patients.…”

Section: Consultation Support System For Patients With Liver Diseasesmentioning

confidence: 99%

Seamless support from screening to anti-HCV treatment and HCC/decompensated cirrhosis: Subsidy programs for HCV elimination

Setoyama

Tanaka

Kanto

2021

GHM

Self Cite

View full text Add to dashboard Cite

Viral hepatitis poses a major public health problem in Japan. Chronic viral hepatitis is a progressive liver disease that eventually develops into liver cirrhosis and liver cancer. Since nucleic acid analog therapy for hepatitis B and interferon-free therapy for hepatitis C have made it possible to control the disease status or eliminate the viruses, it is very important that more people receive hepatitis virus tests to confirm the presence of infection at an early stage, and that patients with hepatitis detected by the tests receive appropriate medical care. Currently, the government of Japan is implementing comprehensive measures for hepatitis control based on five key strategies. Moreover, the goal listed in the Basic Guidelines on Hepatitis Measures is to reduce the frequency of progression of hepatitis to cirrhosis or liver cancer through a scheme consisting of testing people for hepatitis, getting those who test positive to visit a medical institution and receive treatment, and providing appropriate and high-quality hepatitis care through specialized medical institutions and regional core centers for the management of liver disease. To achieve the goal, various subsidy programs including an expense subsidy system for hepatitis treatment have been implemented in Japan. It is important for healthcare professionals to have sufficient knowledge of public support for efficient hepatitis C virus (HCV)-related liver disease detection and care.

show abstract

“…The most common type of educational activity was distribution of posters/leaflets, newspaper advertisements/articles, and events/symposiums. Other activities included dissemination of information through websites and social media, traveling liver disease seminars, and hepatitis testing (11).…”

Section: (P4)mentioning

confidence: 99%

Nationwide awareness-raising program for viral hepatitis in Japan: the "<i>Shitte kan-en</i>" project

Takeuchi

Ohara

Kanto

2021

GHM

Self Cite

View full text Add to dashboard Cite

Chronic viral hepatitis is one of the most widespread infectious diseases in Japan. In the 2009 financial year, the Japanese government enacted the Basic Act on Hepatitis Measures, followed by the Basic Guidelines for Promotion of Control Measures for Hepatitis 2 years later. The guidelines emphasize the importance of provision and dissemination of accurate information on viral hepatitis and public awareness-raising. A subsidy program on hepatitis was therefore launched by the Ministry of Health, Labour and Welfare in 2011, called "Shitte kan-en" (in English, "Let's learn about hepatitis"), and involves popular Japanese actors and singers. The project started awareness-raising activities in the 2013 financial year, as the "National Campaign Project for Hepatitis Measures". It aims to communicate concise and accurate information about hepatitis and the necessity of testing for viral hepatitis. It also encourages citizens to take a positive approach to early detection and treatment. To date, the main initiatives of the project are as follows: i) celebrity visits to prefectural governors to draw attention to the condition, ii) educational events in cooperation with hepatologists in regional core hospitals, iii) support for partner companies' hepatitis awareness activities in workplaces, and iv) support for the activities of program promoters. Targeting approaches to particular groups is likely to be key to success for general awareness-raising. Evaluation of the effectiveness of this multifaceted approach is warranted to reduce the undiagnosed population and improve the link between testing and care for viral hepatitis in Japan.

show abstract

Nationwide survey on activities of regional core centers for the management of liver disease in Japan: Cumulative analyses by the Hepatitis Information Center 2009–2017

Cited by 9 publications

References 2 publications

Characteristics of patients aged over 75 years with hepatitis C virus infection treated with direct‐acting antivirals in Japan: Evidence based on the nationwide, real‐world database in Japan

Characteristics of patients aged over 75 years with hepatitis C virus infection treated with direct‐acting antivirals in Japan: Evidence based on the nationwide, real‐world database in Japan

Seamless support from screening to anti-HCV treatment and HCC/decompensated cirrhosis: Subsidy programs for HCV elimination

Nationwide awareness-raising program for viral hepatitis in Japan: the "<i>Shitte kan-en</i>" project

Contact Info

Product

Resources

About